Valuation: Spero Therapeutics, Inc.

Market Cap 64.06M 56.94M 52.78M 48.02M 90.61M 6.08B 92.06M 634M 249M 3.17B 240M 235M 10.11B P/E 2026 *
-1.9x
P/E 2027 * -10.5x
Enterprise Value 64.06M 56.94M 52.78M 48.02M 90.61M 6.08B 92.06M 634M 249M 3.17B 240M 235M 10.11B EV / Sales 2026 *
248x
EV / Sales 2027 * -
Free-Float
77.34%
Yield 2026 *
-
Yield 2027 * -
1 day-2.65%
1 week-8.33%
Current month-9.09%
1 month-0.90%
3 months-29.94%
6 months-58.96%
Current year-52.79%
1 week 1.09
Extreme 1.09
1.22
1 month 1.09
Extreme 1.09
1.44
Current year 1.08
Extreme 1.08
3.08
1 year 1.08
Extreme 1.08
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
18.35
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 10/01/2025
Chief Tech/Sci/R&D Officer 69 27/07/2026
Chief Operating Officer 58 01/02/2023
Director TitleAgeSince
Chairman 69 01/01/2014
Director/Board Member 62 01/09/2015
Chairman 56 10/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Free

Chief Technology Officer

486,986 0.8411%
4/5/26 Sell

Chief Executive Officer

-25,240 0.0436%
6/2/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%-8.33%-53.19%-3.51% 64.06M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.93%-2.34%+33.67%+76.79% 37.2B
Weighted average by Cap. -2.30%-1.21%+43.54%+88.56%

Financials

2026 *2027 *
Net sales 258K 229K 213K 193K 365K 24.49M 371K 2.56M 1M 12.78M 968K 948K 40.73M -
Net income -33.46M -29.74M -27.56M -25.08M -47.32M -3.18B -48.08M -331M -130M -1.66B -126M -123M -5.28B -51.5M -45.78M -42.43M -38.6M -72.85M -4.89B -74.02M -510M -200M -2.55B -193M -189M -8.13B
Net Debt - -
Projected Income Statement - Annual - Spero Therapeutics, Inc.
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
16/10/26 US$1.100 -2.65% 361,279
15/10/26 US$1.130 +0.89% 233,830
14/10/26 US$1.120 -2.61% 697,610
13/10/26 US$1.150 -2.54% 272,493
12/10/26 US$1.180 -1.67% 414,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Spero Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.100USD
Average target price
5.000USD
Spread / Average Target
+354.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Spero Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SPRO Stock